The annual general meeting 2011 document summarizes SCA Group's performance in 2010 and strategic priorities. Key points include: SCA is a global hygiene and paper company with SEK 109 billion in net sales and 45,000 employees. In 2010, EBIT was flat at SEK 9.6 billion. Personal care, tissue, packaging, and forest products are the main business areas. Growth priorities are emerging markets, cost reductions, and increased innovation. Sustainability initiatives are reducing costs and risks. Europe's largest private forests are a valuable renewable asset.
http://www.sca.com/ir The presentation of SCA CFO Lennart Persson at the UBS European Conference in London, UK.
http://www.facebook.com/SCa
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
You are welcome to read or download SCA's presentation at the ABG SC Consumer Goods Seminar in Stockholm, Sweden.
SCA was represented by Johan Karlsson, Vice President, Investor Relations.
http://www.sca.com/ir
SCA is a global hygiene products and paper company with net sales of SEK 109 billion in 2010. It has 45,000 employees in over 100 countries. In 2010, personal care accounted for 29% of sales and 30% of EBIT, tissue 27% of sales and 25% of EBIT, packaging 22% of sales and 16% of EBIT, and forest products 15% of sales and 16% of EBIT. SCA aims to grow through cost reductions, efficiency programs, innovations, and expanding in emerging markets where hygiene product penetration is currently low. Raw material costs increased significantly in 2010 but SCA increased prices for packaging and publication paper. SCA reported stable EBIT and higher earnings per
Profit before tax rose 6% (10% excl. exchange rate effects) to SEK 8,492m. Net sales decreased by 2% (increased by 5% excl. exchange rate effects and divestments) to SEK 109,142m. Cash flow from current operations was SEK 7,399m. Proposed dividend 4.00 SEK (3.70)per share.
http://www.sca.com
http://www.sca.com/ir SCA CFO Lennart persson held a presentation at the TMC seminar on September 22, 2011.
He talked about hygiene products sales increase, strategic focus areas, brands, market positions, innovation, growth potential for hygiene products, emerging markets, sustainability as a business driver.
http://www.facebook.com/SCA | http://www.twitter.com/SCAeveryday | http://www.youtube.com/SCAeveryday
http://www.sca.com/ir Mats Berencreutz, Executive Vice President at SCA, hold a presentation at the Handelsbanken consumer seminar in Stockholm, December 2, 2011. The presentation focused on increased sales of hygiene products, strategic focus areas, sustainability, innovation, growth potential for hygiene products and the binding offer for Georgia Pacific’s European tissue operations.
http://www.facebook.com/SCA
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
http://www.sca.com/ir The presentation of SCA CFO Lennart Persson at the UBS European Conference in London, UK.
http://www.facebook.com/SCa
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
You are welcome to read or download SCA's presentation at the ABG SC Consumer Goods Seminar in Stockholm, Sweden.
SCA was represented by Johan Karlsson, Vice President, Investor Relations.
http://www.sca.com/ir
SCA is a global hygiene products and paper company with net sales of SEK 109 billion in 2010. It has 45,000 employees in over 100 countries. In 2010, personal care accounted for 29% of sales and 30% of EBIT, tissue 27% of sales and 25% of EBIT, packaging 22% of sales and 16% of EBIT, and forest products 15% of sales and 16% of EBIT. SCA aims to grow through cost reductions, efficiency programs, innovations, and expanding in emerging markets where hygiene product penetration is currently low. Raw material costs increased significantly in 2010 but SCA increased prices for packaging and publication paper. SCA reported stable EBIT and higher earnings per
Profit before tax rose 6% (10% excl. exchange rate effects) to SEK 8,492m. Net sales decreased by 2% (increased by 5% excl. exchange rate effects and divestments) to SEK 109,142m. Cash flow from current operations was SEK 7,399m. Proposed dividend 4.00 SEK (3.70)per share.
http://www.sca.com
http://www.sca.com/ir SCA CFO Lennart persson held a presentation at the TMC seminar on September 22, 2011.
He talked about hygiene products sales increase, strategic focus areas, brands, market positions, innovation, growth potential for hygiene products, emerging markets, sustainability as a business driver.
http://www.facebook.com/SCA | http://www.twitter.com/SCAeveryday | http://www.youtube.com/SCAeveryday
http://www.sca.com/ir Mats Berencreutz, Executive Vice President at SCA, hold a presentation at the Handelsbanken consumer seminar in Stockholm, December 2, 2011. The presentation focused on increased sales of hygiene products, strategic focus areas, sustainability, innovation, growth potential for hygiene products and the binding offer for Georgia Pacific’s European tissue operations.
http://www.facebook.com/SCA
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
SCA has offered EUR 1.32 billion to acquire Georgia-Pacific's European tissue business. The acquisition is expected to increase SCA's earnings per share in the first year and by approximately SEK 1.70 with fully realized synergies. The acquisition would create a leading European tissue company and strengthen SCA's product offering, geographic reach, and presence in key markets and the AFH tissue industry. Substantial synergies of EUR 125 million are expected from improved supply chain efficiency and SG&A, enhancing tissue EBIT margins by 2-2.5 percentage points within 3 years.
The document summarizes information about SCA Group, a leading global hygiene and forest products company. Some key details include:
- SCA Group has annual sales of SEK 99 billion, 44,000 employees, and sells products in about 100 countries.
- Major brands and market positions include TENA and Tork as leading global brands, China's third largest tissue company, and Europe's largest private forest owner.
- The company has undergone transformation through acquisitions, divestments, efficiency programs, and investments in emerging markets to drive growth.
- Financial targets include annual organic sales growth of 5-7% for Personal Care and 3-4% for Tissue, and a return on capital employed
This document summarizes a presentation given by Lennart Persson, CFO of SCA, a global hygiene products and paper company, at a conference on March 16, 2010. SCA has annual net sales of SEK 111 billion and approximately 50,000 employees worldwide. The presentation outlines SCA's strategic direction, which includes cost reduction initiatives, supply chain rationalization, tissue and personal care product innovations, and growth in emerging markets through increased penetration. Raw material prices for pulp and recovered paper have increased substantially since early 2009.
SCA Group is a global hygiene and forest products company with net sales of SEK 106 billion in 2011, they have acquired Georgia-Pacific's European tissue operations and Everbeauty to become a leading hygiene company, and they have divested their packaging business while focusing on growing their hygiene products organically and through acquisitions in personal care and tissue.
SCA's presentation by Kersti Strandqvist, SVP Sustainability, at the Cheuvreux Climate Change 6 conference in Paris, May 6, 2011.
http://www.sca.com/sustainability
Stora Enso Annual General Meeting, 2009-04-01Stora Enso
The document summarizes the key topics discussed at an annual general meeting on April 1, 2009 for a company. It provides an overview of the challenging market conditions in 2008 due to high costs and weakening demand. It discusses the company's actions to reduce costs and capacity while preserving cash flow. Financial results for 2008 showed declines in sales, profits and margins compared to 2007. The company outlined further actions and cost savings plans for 2009 to safeguard cash flow during difficult market conditions.
The document summarizes an annual general meeting for Summit PLC held on July 18, 2012. It discusses Summit's focus on key drug development programs, including SMT C1100 for Duchenne Muscular Dystrophy, SMT 19969 for Clostridium difficile infection, and developing inhibitors of OGA for tauopathies like Alzheimer's disease. It outlines upcoming milestones for these programs within the next 12 months and an outlook that achieving these milestones could lead to commercial deals and significant value growth for the company.
The document summarizes an interim report for SCA for Q3 2012. It found that sales increased 16% due to acquisitions in tissue and strong growth in emerging markets, particularly for personal care and tissue products. EBIT increased 20% due to acquisitions, higher volumes, lower raw material costs, and cost savings. However, forest products faced lower demand and prices in European markets. Overall the hygiene business saw good sales growth and profitability while forest products faced challenging market conditions.
The interim report summarizes the company's performance in the second quarter of 2012. It notes that the global economy slowed in 2012 due to issues in Western Europe. The hygiene products business saw good growth in emerging markets. Forest product sales and prices decreased in Europe. The company acquired several businesses and divested its packaging business. Sales increased 2% year-over-year due to growth in hygiene products, while EBIT grew 16% on higher volumes and lower costs. The personal care and tissue segments saw higher sales and profits from emerging markets. Forest products struggled with lower prices.
Jan Johansson, CEO of SCA, discussed the company's major changes in 2012 including divesting packaging businesses, acquiring Georgia-Pacific's European tissue operations, and establishing a joint venture in Australia/New Zealand. SCA also acquired several hygiene product companies. Johansson outlined SCA's strategic priorities of efficiency, innovation, and growth. SCA has leading market positions globally and regionally in tissue, solid wood products, and hygiene products. Despite economic challenges, hygiene products show growth in emerging markets.
The interim report summarizes SCA's financial results for the first quarter of 2011. Key points include:
- Sales increased 6% compared to Q1 2010, with growth in hygiene and packaging businesses, particularly in emerging markets.
- Earnings before interest and tax (EBIT) increased 10%, though costs were significantly higher, including a SEK 1.3 billion increase in raw material costs.
- Profit before tax also increased 10% compared to Q1 2010.
Net sales rose 15% (6% excluding exchange rate effects) to SEK 27,958m (24,234). Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, was 6%. Operating profit, excluding items affecting comparability, rose 9% to SEK 2,872m (2,630).
The operating margin, excluding items affecting comparability, was 10.3% (10.9). Profit before tax, excluding items affecting comparability, rose 11% to SEK 2,602m (2,342). Items affecting comparability totaled SEK -122m (-247). Earnings per share were SEK 2.43 (2.12). Return on capital employed, excluding items affecting comparability, was 11.2% (11.0). Cash flow from current operations was SEK 1,246m (667).
The document provides an interim report for the first quarter of 2012 summarizing major business changes and financial results compared to the same period in 2011 and the previous quarter. Key points include the acquisition of several hygiene product companies and divestment of packaging businesses. Sales increased 4% year-over-year due to higher volumes and prices in hygiene products and higher forest product volumes. EBIT increased 7% excluding items from higher volumes and lower raw material costs.
Morgan Stanley conference. Jan Johansson, President and CEO of SCA, provided an overview of the company. SCA is one of the world's largest hygiene products companies, with net sales of SEK 111 billion and 45,000 employees globally. Their hygiene business has grown significantly, now making up 60% of net sales compared to 42% in 1999. SCA has leading market positions globally and regionally within tissue, incontinence care, baby diapers, and feminine care. They outlined their strategic focus on growth in emerging markets and increased innovation to strengthen their market positions.
Operating profit, excl. restruct. costs, decreased by 5% (increased by 1% excl. exchange rate effects) to SEK 4,262m. Net sales decreased by 2% (increased by 5% excl. exchange rate effects and divestments) to SEK 52,064m. Earnings per share rose 8% (13% excl. exchange rate effects) to SEK 3.85.
More info available on http://www.sca.com/ir
The SCA reported on its performance in 2012. Key points include:
- Sales grew 11% due to acquisitions and strong growth in emerging markets, though the forest products business declined.
- EBIT increased 17% due to higher volumes, lower costs, and cost savings programs.
- In Q4, sales grew 21% and EBIT grew 16% compared to Q4 2011, led by growth in the hygiene business in emerging markets.
- For the full year, net income increased significantly and cash flow grew 30%, while debt was reduced.
- The company continued executing its strategy around efficiency, innovation, growth and sustainability.
SCA has offered EUR 1.32 billion to acquire Georgia-Pacific's European tissue business. The acquisition is expected to increase SCA's earnings per share in the first year and by approximately SEK 1.70 with fully realized synergies. The acquisition would create a leading European tissue company and strengthen SCA's product offering, geographic reach, and presence in key markets and the AFH tissue industry. Substantial synergies of EUR 125 million are expected from improved supply chain efficiency and SG&A, enhancing tissue EBIT margins by 2-2.5 percentage points within 3 years.
The document summarizes information about SCA Group, a leading global hygiene and forest products company. Some key details include:
- SCA Group has annual sales of SEK 99 billion, 44,000 employees, and sells products in about 100 countries.
- Major brands and market positions include TENA and Tork as leading global brands, China's third largest tissue company, and Europe's largest private forest owner.
- The company has undergone transformation through acquisitions, divestments, efficiency programs, and investments in emerging markets to drive growth.
- Financial targets include annual organic sales growth of 5-7% for Personal Care and 3-4% for Tissue, and a return on capital employed
This document summarizes a presentation given by Lennart Persson, CFO of SCA, a global hygiene products and paper company, at a conference on March 16, 2010. SCA has annual net sales of SEK 111 billion and approximately 50,000 employees worldwide. The presentation outlines SCA's strategic direction, which includes cost reduction initiatives, supply chain rationalization, tissue and personal care product innovations, and growth in emerging markets through increased penetration. Raw material prices for pulp and recovered paper have increased substantially since early 2009.
SCA Group is a global hygiene and forest products company with net sales of SEK 106 billion in 2011, they have acquired Georgia-Pacific's European tissue operations and Everbeauty to become a leading hygiene company, and they have divested their packaging business while focusing on growing their hygiene products organically and through acquisitions in personal care and tissue.
SCA's presentation by Kersti Strandqvist, SVP Sustainability, at the Cheuvreux Climate Change 6 conference in Paris, May 6, 2011.
http://www.sca.com/sustainability
Stora Enso Annual General Meeting, 2009-04-01Stora Enso
The document summarizes the key topics discussed at an annual general meeting on April 1, 2009 for a company. It provides an overview of the challenging market conditions in 2008 due to high costs and weakening demand. It discusses the company's actions to reduce costs and capacity while preserving cash flow. Financial results for 2008 showed declines in sales, profits and margins compared to 2007. The company outlined further actions and cost savings plans for 2009 to safeguard cash flow during difficult market conditions.
The document summarizes an annual general meeting for Summit PLC held on July 18, 2012. It discusses Summit's focus on key drug development programs, including SMT C1100 for Duchenne Muscular Dystrophy, SMT 19969 for Clostridium difficile infection, and developing inhibitors of OGA for tauopathies like Alzheimer's disease. It outlines upcoming milestones for these programs within the next 12 months and an outlook that achieving these milestones could lead to commercial deals and significant value growth for the company.
The document summarizes an interim report for SCA for Q3 2012. It found that sales increased 16% due to acquisitions in tissue and strong growth in emerging markets, particularly for personal care and tissue products. EBIT increased 20% due to acquisitions, higher volumes, lower raw material costs, and cost savings. However, forest products faced lower demand and prices in European markets. Overall the hygiene business saw good sales growth and profitability while forest products faced challenging market conditions.
The interim report summarizes the company's performance in the second quarter of 2012. It notes that the global economy slowed in 2012 due to issues in Western Europe. The hygiene products business saw good growth in emerging markets. Forest product sales and prices decreased in Europe. The company acquired several businesses and divested its packaging business. Sales increased 2% year-over-year due to growth in hygiene products, while EBIT grew 16% on higher volumes and lower costs. The personal care and tissue segments saw higher sales and profits from emerging markets. Forest products struggled with lower prices.
Jan Johansson, CEO of SCA, discussed the company's major changes in 2012 including divesting packaging businesses, acquiring Georgia-Pacific's European tissue operations, and establishing a joint venture in Australia/New Zealand. SCA also acquired several hygiene product companies. Johansson outlined SCA's strategic priorities of efficiency, innovation, and growth. SCA has leading market positions globally and regionally in tissue, solid wood products, and hygiene products. Despite economic challenges, hygiene products show growth in emerging markets.
The interim report summarizes SCA's financial results for the first quarter of 2011. Key points include:
- Sales increased 6% compared to Q1 2010, with growth in hygiene and packaging businesses, particularly in emerging markets.
- Earnings before interest and tax (EBIT) increased 10%, though costs were significantly higher, including a SEK 1.3 billion increase in raw material costs.
- Profit before tax also increased 10% compared to Q1 2010.
Net sales rose 15% (6% excluding exchange rate effects) to SEK 27,958m (24,234). Organic sales growth, which excludes exchange rate effects, acquisitions and divestments, was 6%. Operating profit, excluding items affecting comparability, rose 9% to SEK 2,872m (2,630).
The operating margin, excluding items affecting comparability, was 10.3% (10.9). Profit before tax, excluding items affecting comparability, rose 11% to SEK 2,602m (2,342). Items affecting comparability totaled SEK -122m (-247). Earnings per share were SEK 2.43 (2.12). Return on capital employed, excluding items affecting comparability, was 11.2% (11.0). Cash flow from current operations was SEK 1,246m (667).
The document provides an interim report for the first quarter of 2012 summarizing major business changes and financial results compared to the same period in 2011 and the previous quarter. Key points include the acquisition of several hygiene product companies and divestment of packaging businesses. Sales increased 4% year-over-year due to higher volumes and prices in hygiene products and higher forest product volumes. EBIT increased 7% excluding items from higher volumes and lower raw material costs.
Morgan Stanley conference. Jan Johansson, President and CEO of SCA, provided an overview of the company. SCA is one of the world's largest hygiene products companies, with net sales of SEK 111 billion and 45,000 employees globally. Their hygiene business has grown significantly, now making up 60% of net sales compared to 42% in 1999. SCA has leading market positions globally and regionally within tissue, incontinence care, baby diapers, and feminine care. They outlined their strategic focus on growth in emerging markets and increased innovation to strengthen their market positions.
Operating profit, excl. restruct. costs, decreased by 5% (increased by 1% excl. exchange rate effects) to SEK 4,262m. Net sales decreased by 2% (increased by 5% excl. exchange rate effects and divestments) to SEK 52,064m. Earnings per share rose 8% (13% excl. exchange rate effects) to SEK 3.85.
More info available on http://www.sca.com/ir
The SCA reported on its performance in 2012. Key points include:
- Sales grew 11% due to acquisitions and strong growth in emerging markets, though the forest products business declined.
- EBIT increased 17% due to higher volumes, lower costs, and cost savings programs.
- In Q4, sales grew 21% and EBIT grew 16% compared to Q4 2011, led by growth in the hygiene business in emerging markets.
- For the full year, net income increased significantly and cash flow grew 30%, while debt was reduced.
- The company continued executing its strategy around efficiency, innovation, growth and sustainability.
- SCA reported good organic growth in sales and operating profit in Q2 2015, with strong growth in emerging markets. Cash flow was also strong.
- Personal care sales grew 12% with 6% organic growth, driven by price increases, higher volumes, and cost savings. Tissue sales grew 15% with 4% organic growth.
- Operating profit increased for both personal care and tissue, despite higher raw material costs. Forest products profit grew 39% on higher prices and volumes.
- The report highlighted continued strategic priorities of efficiency, innovation, and profitable growth, with several new product launches and investments.
The document summarizes a presentation given by Jan Johansson, President and CEO of SCA Group, at a UBS conference in Boston. It provides details on SCA's financial results, including sales of SEK 99 billion and 44,000 employees. It also outlines SCA's transformation through acquisitions, divestments, efficiency programs, and focus on hygiene, tissue, and forest products. SCA's priorities are described as efficiency, innovation, and growth to drive sales increases, especially in emerging markets.
This document summarizes a presentation by Lennart Persson, CFO of SCA, a global hygiene products and paper company. Key points include: SCA has annual net sales of SEK 111 billion and approximately 50,000 employees. SCA's strategic focus areas are strengthening positions in personal care, tissue, and packaging, driving growth in emerging markets, increasing value-added products, and improving efficiency. SCA is also implementing a restructuring program in packaging to reduce costs in response to the economic downturn.
SCA hosted the Capital Markets Day in Stockholm. The Group-wide financial targets and strategy remains with a focus on efficiency, innovation, growth and sustainability. The target for return on capital employed for Tissue and Forest Products has been adjusted. In recent years, SCA has completed hygiene acquisitions and divested for example the packaging operations. In order to further strengthen profitability in the hygiene operations, measures are initiated for decreased costs and improved efficiency.
http://www.sca.com/ir September 19, 2011 SCA hosted the Capital Markets Day in Stockholm. The strategy of recent years of focusing on costs, cash flow, capital efficiency and innovation remains firmly in place. Increased growth was added to the Group’s strategic agenda in 2010.
http://www.facebook.com/SCA
http://www.twitter.com/SCAeveryday
http://www.youtube.com/SCAeveryday
Biological solutions in a chemical world, Green Polymer Chemistry 2012Thomas Schäfer
Novozymes is the world leader in industrial enzymes, with a 47% market share. It has over 60 years of experience in the enzyme business and focuses on delivering biological solutions to replace chemicals. Novozymes' technologies help customers reduce CO2 emissions and save energy and raw materials. Its vision is to enable a biobased society with renewable fuels, chemicals, food and materials produced from agricultural waste through large-scale conversion of sugars using enzyme systems.
Stiglitz Christian. Packaging waste management following the extended produce...ECO-invest
This document provides an overview of packaging waste management in Europe following the Extended Producer Responsibility (EPR) principle between 1995 and 2012. It discusses key EU waste stream regulations based on EPR, including for packaging and packaging waste. It then details the Austrian experience with the EPR system for packaging waste management operated by ARA, covering topics like collection and recovery rates, involved partners, and services provided.
Philips is a 120-year-old global company headquartered in Amsterdam that generates over €25 billion in annual sales across its healthcare, lighting, and consumer lifestyle businesses. It employs over 119,000 people globally and invests €1.6 billion annually in R&D. Philips aims to be the leading company in health and well-being through meaningful innovations that improve people's lives. It focuses on aging populations, consumer empowerment, and emerging markets.
Philips is a diversified technology company founded in 1891 operating in over 100 countries. It has four main business segments: Healthcare, Consumer Lifestyle, Lighting, and Lighting. Philips aims to address key societal issues through innovation, sustainability, and building unique leadership positions across its business areas.
Philips is a diversified technology company founded in 1891 headquartered in Amsterdam. It has over 120,000 employees operating in over 100 countries. Its businesses include Healthcare, Consumer Lifestyle, and Lighting. Healthcare accounted for 40% of sales in 2011, focusing on areas like imaging systems, patient care, and home healthcare. Consumer Lifestyle accounted for 26% of sales, with businesses in personal care, health and wellness, and appliances. Lighting accounted for 34% of sales, providing lamps, lighting systems, and luminaires for homes, offices, industry and cities. Philips aims to address key societal issues through sustainable innovations and improving lives.
International Commerce of Organic Products - Situation, Perspectives and Expe...F. Javier Martinez R.
This document provides an overview of the international organic products market and Peru's role in it. It discusses the growing global market for organic products, valued at an estimated $53 billion in 2009. Europe, the United States, and Japan make up the largest markets. The document also summarizes Peru's success in organic agriculture, noting that it is the world's top exporter of organic coffee and cocoa. Peru has developed strong institutions and a legal framework to support its organic sector.
Social media amsterdam april philips final compressedFloris Regouin
This document provides an overview of Philips' strategy for leveraging digital marketing and social media. It discusses how Philips is using social media to create brand preference and discusses a campaign in the Netherlands that led to increased brand preference. It outlines Philips' global consumer care operations and the complex environment it deals with. It then provides guidance on how Philips is organizing itself to support a social media strategy, including setting objectives, roles, and dedicated local teams. Examples are given of how Philips is using social media to improve consumer feedback, support forums, and complaint handling. The overall aim is to improve consumer experience, Net Promoter Score, and cost of non-quality.
The document outlines plans to grow the Dettol brand in India from FY 2009-2011. Key objectives include doubling Dettol's market share, increasing revenues from INR 452 Cr to INR 1095 Cr, and identifying areas for the projected INR 360 Cr growth. Strategies proposed include repositioning Dettol from a germ killer to focus on purification and nourishment, launching new product lines like Dettol Cool variants, Dettol Specialist skincare range, Dettol Kitchen handwash, and Dettol Baby Care. Financial projections estimate these new products and repositioning can help Dettol achieve its objectives and grow revenues to over INR 1098 Cr by FY 2011.
The document outlines the strategy and first quarter 2011 results of a mid-sized European pharmaceutical company. It discusses objectives to expand organically and through acquisitions, develop new products, and pursue geographical expansion into high-growth markets. First quarter 2011 revenue increased 6.4% to €197.8 million, with operating income up 2.9% and net income rising 4.8%. Sales of new products and orphan drugs showed significant growth. The company has a strong financial position and aims to accelerate sales growth through 2013.
Philips is a Dutch multinational conglomerate founded in 1891 headquartered in Amsterdam. In 2011, Philips reported sales of €22.6 billion and employed 122,000 people worldwide across its three main divisions of Healthcare, Consumer Lifestyle, and Lighting. Philips' mission is to improve people's lives through meaningful innovation in health technology and sustainable solutions.
Conferência Santander (somente em inglês)Providência
Providência held its 9th annual conference on August 22, 2008. The conference agenda covered an overview of the company and its two divisions, highlights from the second quarter of 2008, 2Q08 financial results, and the company's outlook. Some key points included strong volume growth in the nonwovens division driven by the startup of new production lines, increased market share in Brazil, higher margins due to efficiency gains, and plans for international expansion through a new production facility in the United States.
The global dental implant market was valued at $2.1 billion in 2007 and is expected to grow at a compound annual rate of 16% to $4 billion by 2011. Europe currently represents 48% of the global market but is expected to see slower growth of 13% compared to the US market's projected growth rate of 21%. The leading manufacturers make up 75-80% of the global market share, with Nobel Biocare being the current leader. Revenue for older implant systems like Restore, Stage-1, and Renova are projected to decline as they reach maturity in the competitive market, while the newer Prima system featuring a patented design is projected to significantly increase in revenue.
SCA creates value by fulfilling the needs of customers and consumers in a spirit of innovation, through continuous efficiency enhancements and with a clear desire to contribute to sustainable development. The Group develops, produces and markets personal care products, tissue, packaging, publication papers and solid-wood products, and has sales in more than 100 countries. In 2010, SCA had annual sales of SEK 109bn and about 45,000 employees.
http://www.sca.com
Claus Fuglsang - Novozymes - Denmark - Stanford Engineering - Jan 30 2012Burton Lee
Novozymes is a global leader in bioinnovation, producing industrial enzymes and microorganisms. It has over 700 products used in 130 countries across 40 industries. Novozymes has a diverse business portfolio including household care, food and beverages, bioenergy, and more. It invests heavily in R&D, with 14% of annual sales reinvested and over 5,800 patents granted or pending. Novozymes leverages its expertise and global market presence across segments to accelerate innovation and maintain its market leader position.
SCA reported strong results for Q2 2016. Organic operating profit growth was strong due to good organic sales growth in hygiene products and emerging markets. Cash flow was also strong. Efficiency gains contributed positively despite provisions for anti-trust and tax cases. The divestment of businesses in Asia closed on April 1 for integration with Vinda. Seven new product innovations were introduced, including for TENA, Okay, Lotus, Zewa, and Tork.
Through continued focus on our strategic priorities profitable growth, innovation and efficiency, we delivered favorable organic sales and earnings growth for the first quarter of 2016.
- Organic sales growth and operating profit increased in Q3 2015 for the Group overall. Emerging markets saw strong growth while mature markets saw modest increases.
- Key events included acquiring Wausau Paper Corp, divesting businesses in Asia to integrate with Vinda, and intended closure of a paper machine to improve efficiency.
- Strategic priorities are increasing efficiency across the value chain and driving innovation and profitable growth.
In 2014 SCA delivered its highest profit before tax ever and good organic sales growth. We increased our operating profit, excluding items affecting comparability, by SEK 1,468m. We achieved this thanks to the continued work with our strategic priorities – growth, innovation and efficiency.
We have presented a report for the second quarter of 2014 with continued sales growth, higher earnings and a higher margin compared with the same period a year ago. During the quarter, several innovations and product launches were carried out under the Libero, Libresse, TENA and Tork brands. The efficiency programs in the hygiene and forest products operations continue to deliver cost savings according to plan. Our Tissue and Forest Products business areas showed significant earnings growth. Personal Care was negatively impacted by higher raw material costs and negative exchange rate effects in emerging markets.
The SCA interim report was published on April 29 at approximately 8.00 CET. At the subsequent press conference CEO Jan Johansson held this presentation.
This is SCAs presentation of the Year-end Report 2013. The presentation was held by CEO Jan Johansson on January 29. SCA further strengthened its position in emerging markets in 2013. During the fourth quarter of 2013, the offer for the Chinese tissue company Vinda was completed, and SCA is today the majority owner of Vinda with 51.4% ownership in the company. SCA decided during the year to invest in local production of hygiene products in India and has launched Libero baby diapers and Tempo consumer tissue in the Indian market.
The efficiency programs in the hygiene and forest products operations are continuing according to plan.
Consolidated net sales for 2013, excluding exchange rate effects and divestments, rose 10% compared with a year ago. The increase is mainly attributable to acquisitions and higher volumes. Operating profit, excluding items affecting comparability, exchange rate effects and divestments, rose 19%. Cost savings, higher volumes, the acquisition in Europe and gains on forest swaps contributed to the earnings improvement. Operating profit for Personal Care and Tissue, excluding items affecting comparability, exchange rate effects and divestments, rose 4% and 27%, respectively. Operating profit for Forest Products, excluding items affecting comparability, rose 35%. Profit before tax, excluding items affecting comparability, exchange rate effects and divestments, rose 25%.
Consolidated net sales for the fourth quarter of 2013, excluding exchange rate effects and divestments, rose 1% compared with the same period a year ago. The increase is mainly attributable to higher volumes. Operating profit, excluding items affecting comparability, exchange rate effects and divestments, rose 31%. Cost savings and gains on forest swaps contributed to the earnings improvement. The corresponding profit for Tissue rose 18%, while profit for Personal Care decreased by 12% as a result of lower earnings for baby diapers associated with an increase in marketing activities. However, incontinence care products and feminine care products had a positive earnings impact. Operating profit for Forest Products, excluding items affecting comparability, rose 188%. Profit before tax, excluding items affecting comparability, exchange rate effects and divestments, rose 38%.
SCA´s net sales for the first nine months rose 14% excluding exchange rate effects and divestments and amounted to SEK 66,577m. Operating profit rose 15% excluding items affecting comparability and exchange rate effects to SEK 6,885m (6,224).
Consolidated net sales for the first quarter of 2013, excluding exchange rate effects and divestments, rose 20% compared with the same period a year ago. The increase is mainly attributable to acquisitions and higher volumes.
Operating profit excluding exchange rate effects and items affecting comparability rose 25%. The corresponding profit for Personal Care and Tissue rose 27% and 40%, respectively, while profit for Forest Products decreased by 22%. Forest Products includes positive earning effects of SEK 121m attributable to land swaps and negative exchange rate effects of approximately SEK 110m. Profit before tax, excluding exchange rate effects and items affecting comparability, rose 34%. The Group’s operating cash flow improved by 5%, to approximately SEK 1.9bn.
SCA is a leading global hygiene and forest products company. The Group develops and produces sustainable personal care, tissue and forest products. Sales are conducted in about 100 countries under many strong brands. The Group has about 36,000 employees and sales in 2012 amounted to SEK 85bn (EUR 9.8bn). Read more on www.sca.com.
SCA reported its year-end results for 2011. Sales increased 4% over the previous year driven by higher volumes and prices in the hygiene business. EBIT remained flat due to higher raw material costs and currency impacts offsetting the increased sales and cost savings. Profit before tax decreased 3% for the full year. For the fourth quarter, sales increased 1% while EBIT grew 1% as higher prices were offset by increased raw material costs and currency effects. The company proposed a 5% increase in dividend and discussed several strategic acquisitions and divestments.
This document provides an overview of SCA, a global hygiene and paper company. It discusses SCA's business areas, strategy, priorities, and approach to innovation. Specifically:
1) SCA develops, produces, and markets personal care products, tissue, packaging, and forest products. It has sales in over 100 countries and around 45,000 employees.
2) SCA's strategy focuses on sustainably developing value-added products and services within its business areas to improve quality of life. Its strategic priorities are costs/cash flow, capital efficiency, innovation, and growth.
3) SCA prioritizes innovation to drive profitable growth. Its innovation process is based on customer/consumer insights
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
2. SCA Group
A global hygiene products and paper company
Net sales SEK 109bn
45,000 employees and sales in more
than 100 countries
World’s third largest hygiene products
company
Europe’s largest private forest owner
Europe’s second largest packaging
company
2 Annual General Meeting 2011
3. SCA Group
Sales and EBIT split 2010
EBIT split EBIT split
Forest Products Sales split Personal Care
25% 29%
15% 22%
27%
36%
16% 30%
Packaging Tissue
3 Annual General Meeting 2011
4. Leading market positions
Global and regional
Nordic region
Incontinence care: 1
Baby diapers: 1
North America AFH tissue: 1
AFH tissue: 3 Consumer tissue: 2
Incontinence care: 3
Europe
Tissue: 1
Corrugated board: 2
Mexico Baby diapers: 3
Incontinence care: 1 Incontinence care: 1
Tissue: 2
Privately owned forests: 1
Feminine care: 3
Baby diapers: 3 Global
Incontinence care: 1
Colombia
AFH tissue: 3 Australia
Incontinence care: 1
Feminine care: 1 Feminine care: 1
Tissue: 1 Incontinence care: 1
Tissue: 2
4 Annual General Meeting 2011
5. Strategic Priorities
Cost reductions in all Efficiency programs in Personal Care SCA Group 5%*
business areas of Packaging and Forest Thin baby diaper
SEK 1bn Products Personal Care 2%**
TENA Ultra thins
Emerging markets 10%**
Cash flow from Closure/Divestment Strong TENA value
current operations: of 18 packaging units assortment Tissue 2%**
SEK 7.4bn Emerging markets 6%**
Supply chain Tissue
excellence and asset Tork Xpressnap Packaging 20%*
utilization programs in Café
Tissue Europe Tork Performance Forest Products 3%**
Tempo ice
Restructuring program
in Baby diapers in Packaging
Europe
Trueflo
New tissue plant in ZeoCool
Mexico
Forest Products
New Personal Care Increased value
plant in Russia added
* Adjusted for exchange rate movements,
divestments and closures
* * Adjusted for exchange rate movements
5 Annual General Meeting 2011
6. Growth
High potential in markets with low penetration
Usage of hygiene products
Units/capita/year Units/child/year Units/woman/year Kg/capita/year
Penetration
in mature
markets
around 35%
North America Western Europe Eastern Europe Latin America Asia
6 Annual General Meeting 2011
7. Growth
SCA’s growth markets
Latin America
Strong SCA positions
South East Asia Good market growth
Favourable socio-demographics
Eastern Europe
/Russia
Middle East Good market growth
Favourable socio-demographics
China Incontinence care products
7 Annual General Meeting 2011
8. Increased pace of innovation
Strengthens market positions
8 Annual General Meeting 2011
9. Full year 2010 results
SEKm Change, Change,
unless otherwise stated 2010 2009 % %**
Net sales 109,142 110,857 -2 5***
EBIT* 9,608 9,648 0 4
EBIT margin* (%) 8.8 8.7
Profit before tax* 8,492 8,004 6 10
Earnings per share (SEK) 7.90 6.78 17
Cash flow from current operations 7,399 11,490 -36
Debt/Equity ratio 0.51 0.60
* Excluding restructuring cost
** Adjusted for exchange rate movements
*** Adjusted for exchange rate movements and divestments
9 Annual General Meeting 2011
10. Net debt
And debt payment capacity
SEKm Net debt decreased SEK 6bn %
36% 40%
33% 35% 33%
10 Annual General Meeting 2011
11. Personal Care
SEKm
Investment in local production in Russia
25,027 25,716
Acquisition of third largest baby diapers business
2%*
in Mexico
Restructuring program in baby diapers in Europe
Growth
Net sales 2010 2009 TENA has increased market share
Incontinence care products in China
Feminine care products launched in Malaysia
3,235
2,922** Tampons launched in Sweden and the Netherlands
-10%** Extended range of Libero baby care products
Emerging market sales increased 10%*
Innovation
EBIT 2010 2009 TENA Ultra Thins
Thin baby diapers
EBIT margin 11.7%** 12.6%
Strong TENA value assortment
* Adjusted for exchange rate movements
** Excluding restructuring costs
11 Annual General Meeting 2011
12. Tissue
SEKm
Investment in new tissue plant in Mexico
39,870 41,425
European brand migration project
2%*
Implementation of price increases
Growth
Tork has gained market share in Europe
and North America
Net sales 2010 2009
Emerging market sales increased 6%*
3,946
Innovation
3,041 Tork Xpressnap Café
Tork Performance
-23% Tempo Ice
Tempo Kids
Tempo toilet tissue
EBIT 2010 2009
EBIT margin 7.6% 9.5%
* Adjusted for exchange rate movements
12 Annual General Meeting 2011
13. Packaging
SEKm
29,633
28,359
Finalized restructuring program
20%* Annualized savings of slightly more than
SEK 1bn
Divestment of the Asian packaging
operation
Annual sales of USD 250m
Net sales 2010 2009
Price increases
1,577**
Innovation
282%** Trueflo
413** ZeoCool
EBIT 2010 2009
EBIT margin 5.3%** 1.5%**
* Adjusted for exchange rate movements, divestments and closures
** Excluding restructuring costs
13 Annual General Meeting 2011
14. Forest Products
SEKm
17,123 16,983
Efficiency project at Ortviken paper mill
3%*
Creation of Gällö Timber AB
Deliveries of FSC certified publication
papers increased 35 %
Net sales 2010 2009
2,455** 2,503
-2%**
EBIT 2010 2009
EBIT margin 14.3%** 14.7%
* Adjusted for exchange rate movements
** Excluding restructuring costs
14 Annual General Meeting 2011
15. Corporate sustainability
New business opportunities and reduced cost
New business opportunities
Increased access to products in emerging
markets
Incontinence training of 5,000 nurses in
China
Renewable energy
Reduced cost and reduced risk
1,300 energy-efficiency initiatives have
reduced cost by SEK 600m
New global supplier standard for the hygiene
business reduces supply chain risk
15 Annual General Meeting 2011
16. The Forest
A valuable asset
Europe’s largest private forest owner – FSC certified
Annual net growth of 1%
Raw material integration and potential for electricity generation
Our forests absorb as much carbon dioxide as is discharged from our
entire production
If the worlds forests were managed the same way as SCA’s that would
solve a big part of the climate change problem
16 Annual General Meeting 2011
17. SCA Group Strategic Priorities
A stronger SCA
17 Annual General Meeting 2011